Trial Profile
Phase 1 Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 May 2015
Price :
$35
*
At a glance
- Drugs Ruxotemitide (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Sep 2011 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.